These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 37316799

  • 1. The Rac inhibitor HV-107 as a potential therapeutic for metastatic breast cancer.
    Crespo GV, Ortiz J, O'Farrill EH, Vlaar CP, Inyushin M, Kucheryavykh Y, Kucheryavykh L.
    Mol Med; 2023 Jun 14; 29(1):75. PubMed ID: 37316799
    [Abstract] [Full Text] [Related]

  • 2. Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models.
    Torres-Sanchez A, Rivera-Robles M, Castillo-Pichardo L, Martínez-Ferrer M, Dorta-Estremera SM, Dharmawardhane S.
    Front Oncol; 2023 Jun 14; 13():1152458. PubMed ID: 37397366
    [Abstract] [Full Text] [Related]

  • 3. Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase.
    Montalvo-Ortiz BL, Castillo-Pichardo L, Hernández E, Humphries-Bickley T, De la Mota-Peynado A, Cubano LA, Vlaar CP, Dharmawardhane S.
    J Biol Chem; 2012 Apr 13; 287(16):13228-38. PubMed ID: 22383527
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer.
    Cruz-Collazo A, Ruiz-Calderon JF, Picon H, Borrero-Garcia LD, Lopez I, Castillo-Pichardo L, Del Mar Maldonado M, Duconge J, Medina JI, Bayro MJ, Hernández-O'Farrill E, Vlaar CP, Dharmawardhane S.
    Mol Cancer Ther; 2021 Dec 13; 20(12):2420-2432. PubMed ID: 34607932
    [Abstract] [Full Text] [Related]

  • 5. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD, Bai WQ, Zhai XT, Sun LP, Zhen YS, Li ZR, Miao QF.
    Mil Med Res; 2021 Dec 09; 8(1):63. PubMed ID: 34879870
    [Abstract] [Full Text] [Related]

  • 6. Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK.
    Wu Q, Ma X, Jin Z, Ni R, Pan Y, Yang G.
    J Ethnopharmacol; 2023 Oct 28; 315():116644. PubMed ID: 37196814
    [Abstract] [Full Text] [Related]

  • 7. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
    Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT.
    Breast Cancer Res Treat; 2019 Jun 28; 175(2):339-351. PubMed ID: 30826934
    [Abstract] [Full Text] [Related]

  • 8. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
    Xu S, Sun X, Luo L, Yang Y, Guo Q, Tang S, Jiang Z, Li Y, Han J, Gan W, Yang F, Zhang X, Liu Y, Sun C, He J, Liu M, Zuo D, Zhu W, Wu Y.
    Biomed Pharmacother; 2022 Nov 28; 155():113537. PubMed ID: 36113258
    [Abstract] [Full Text] [Related]

  • 9. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y, Hu S, Chen Y, Zhang X, Gao H, Tian J, Chen J.
    Phytomedicine; 2023 Sep 28; 118():154924. PubMed ID: 37393829
    [Abstract] [Full Text] [Related]

  • 10. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T, Sudhakar G, Marepally S, Patel A, Banerjee R, Singh M.
    Mol Pharm; 2015 Apr 06; 12(4):1105-20. PubMed ID: 25661724
    [Abstract] [Full Text] [Related]

  • 11. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM.
    Breast Cancer Res; 2012 May 21; 14(3):R79. PubMed ID: 22613095
    [Abstract] [Full Text] [Related]

  • 12. Rubioncolin C, a natural naphthohydroquinone dimer isolated from Rubia yunnanensis, inhibits the proliferation and metastasis by inducing ROS-mediated apoptotic and autophagic cell death in triple-negative breast cancer cells.
    Li L, Wang J, Feng L, Fan J, Wang J, Tan N, Wang Z.
    J Ethnopharmacol; 2021 Sep 15; 277():114184. PubMed ID: 33961996
    [Abstract] [Full Text] [Related]

  • 13. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
    Jin K, Pandey NB, Popel AS.
    Breast Cancer Res; 2018 Jun 14; 20(1):54. PubMed ID: 29898755
    [Abstract] [Full Text] [Related]

  • 14. Characterization of Novel Derivatives of MBQ-167, an inhibitor of the GTP-binding proteins Rac/Cdc42.
    Medina JI, Cruz-Collazo A, Del Mar Maldonado M, Gascot TM, Borrero-Garcia LD, Cooke M, Kazanietz MG, O'Farril EH, Vlaar CP, Dharmawardhane S.
    Cancer Res Commun; 2022 Dec 14; 2(12):1711-1726. PubMed ID: 36861094
    [Abstract] [Full Text] [Related]

  • 15. The Rac Inhibitor EHop-016 Inhibits Mammary Tumor Growth and Metastasis in a Nude Mouse Model.
    Castillo-Pichardo L, Humphries-Bickley T, De La Parra C, Forestier-Roman I, Martinez-Ferrer M, Hernandez E, Vlaar C, Ferrer-Acosta Y, Washington AV, Cubano LA, Rodriguez-Orengo J, Dharmawardhane S.
    Transl Oncol; 2014 Oct 14; 7(5):546-55. PubMed ID: 25389450
    [Abstract] [Full Text] [Related]

  • 16. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
    Wu C, Qiu S, Liu P, Ge Y, Gao X.
    J Ethnopharmacol; 2018 Jan 30; 211():89-100. PubMed ID: 28962890
    [Abstract] [Full Text] [Related]

  • 17. Development of EHop-016: a small molecule inhibitor of Rac.
    Dharmawardhane S, Hernandez E, Vlaar C.
    Enzymes; 2013 Jan 30; 33 Pt A(Pt A):117-46. PubMed ID: 25033803
    [Abstract] [Full Text] [Related]

  • 18. Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer.
    Humphries-Bickley T, Castillo-Pichardo L, Hernandez-O'Farrill E, Borrero-Garcia LD, Forestier-Roman I, Gerena Y, Blanco M, Rivera-Robles MJ, Rodriguez-Medina JR, Cubano LA, Vlaar CP, Dharmawardhane S.
    Mol Cancer Ther; 2017 May 30; 16(5):805-818. PubMed ID: 28450422
    [Abstract] [Full Text] [Related]

  • 19. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Morrison Joly M, Williams MM, Hicks DJ, Jones B, Sanchez V, Young CD, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS.
    Breast Cancer Res; 2017 Jun 30; 19(1):74. PubMed ID: 28666462
    [Abstract] [Full Text] [Related]

  • 20. FGF13 promotes metastasis of triple-negative breast cancer.
    Johnstone CN, Pattison AD, Harrison PF, Powell DR, Lock P, Ernst M, Anderson RL, Beilharz TH.
    Int J Cancer; 2020 Jul 01; 147(1):230-243. PubMed ID: 31957002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.